The US FDA has approved 7 NDAs in May 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 33 novel products in 2022In May 2022, the major highlights drugs were Lilly's Mounjaro (tirzepatide) received the US FDA’s approval for the treatment of adults with Type 2…
